A biotech partnership story about developing stable producer cell lines for scalable gene therapy manufacturing; a forward-looking take on enabling DMD program development.
Key Takeaways
- Addressing a Critical Manufacturing Challenge in DMD Gene Therapy Duchenne muscular dystrophy is a severe
- It is caused by mutations in the DMD gene that prevent the production of functional dystrophin
- Manufacturing is particularly critical for DMD gene therapies